Retrophin completes patient enrollment for Phase 3 FORT study

Retrophin announced completion of patient enrollment in the pivotal Phase 3 FORT Study, which is evaluating the safety and efficacy of fosmetpantotenate for the treatment of pantothenate kinase-associated neurodegeneration, or PKAN, a rare, progressive neurodegenerative genetic disorder. The FORT Study is designed to be registration-enabling in the U.S. and Europe, and top-line results are expected in Q3 of 2019.
https://thefly.com/landingPageNews.php?id=2839887